PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-5.55
Negative P/E while Healthcare median is -2.77. Seth Klarman would scrutinize path to profitability versus peers.
120.38
P/S exceeding 1.5x Healthcare median of 12.24. Jim Chanos would check for potential multiple compression risks.
1.64
P/B 50-90% of Healthcare median of 2.73. Mohnish Pabrai would examine if this discount presents opportunity.
-19.55
Negative FCF while Healthcare median P/FCF is -14.24. Seth Klarman would investigate cash flow improvement potential.
-19.57
Negative operating cash flow while Healthcare median P/OCF is -11.92. Seth Klarman would investigate operational improvement potential.
1.64
Fair value ratio 50-90% of Healthcare median of 2.74. Mohnish Pabrai would examine if this gap presents opportunity.
-4.50%
Negative earnings while Healthcare median yield is -1.42%. Seth Klarman would investigate path to profitability.
-5.12%
Negative FCF while Healthcare median yield is -1.37%. Seth Klarman would investigate cash flow improvement potential.